Entera Bio Names Ex-Pfizer Leader Germano Chairman Ahead of Phase 3 EB613 Launch
Entera Bio appointed former Pfizer Group President Geno J. Germano as chairman of the board effective February 4, 2026, succeeding Gerald Lieberman. The move coincides with plans to advance two oral PTH programs into clinical testing this year, including a Phase 3 EB613 osteoporosis study and a first-in-human hypoparathyroidism trial.
1. Board Appointment
Entera Bio’s board appointed Geno J. Germano as chairman effective February 4, 2026, with Gerald Lieberman stepping down. Germano’s selection follows a strategic review of board composition ahead of key clinical milestones.
2. Pipeline Milestones
Entera plans to initiate a registrational Phase 3 study of EB613 in osteoporosis and launch its first-in-human study of long-acting oral PTH for hypoparathyroidism within 2026, marking its transition to late-stage development.
3. Chairman’s Background
Germano brings over 30 years of biopharma leadership, including serving as Group President of Pfizer’s $14 billion innovative medicines portfolio and co-chairing its Portfolio Strategy and Investment Committee from 2013 to 2016.
4. Strategic Implications
Germano’s expertise in scaling global operations and navigating late-stage development is expected to bolster Entera’s execution on its oral peptide platform and support regulatory alignment for upcoming trials.